Immix Biopharma, Inc. IMMX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.98M+203% | $5.73M+317% | $4.58M+3.1% | $3.97M+78.6% | $1.98M-39.2% | ||
| $4.82M+78.1% | $5.17M+43.0% | $3.08M+4.4% | $2.75M+10.8% | $2.71M+15.6% | ||
| $10.8M+131% | $10.89M+118% | $7.66M+3.6% | $6.72M+42.9% | $4.68M-16.2% | ||
| -$10.8M-131% | -$10.89M-118% | -$7.66M-3.6% | -$6.72M-42.9% | -$4.68M+16.2% | ||
| $717.17K+377% | $216.71K+16.6% | $84.54K-67.1% | $104.06K-66.1% | $150.22K-43.9% | ||
| -$10.09M-123% | -$10.68M-122% | -$7.58M-6.2% | -$6.61M-50.5% | -$4.53M+14.8% | ||
| —— | $11.27K+4.5% | $7.72K-30.7% | $8.91K-13.2% | $9.82K+11.1% | ||
| -$10.09M-122% | -$10.65M-121% | -$7.59M-6.1% | -$6.62M-50.8% | -$4.54M+13.6% | ||
| -$0.18-20.0% | -$0.28-75.0% | -$0.240.0% | -$0.22-46.7% | -$0.15+31.8% | ||
| -$10.71M-131% | -$10.84M-118% | -$7.57M-2.4% | -$6.66M-41.7% | -$4.64M+16.9% | ||
| -$10.8M-131% | -$10.89M-118% | -$7.66M-3.6% | -$6.72M-42.9% | -$4.68M+16.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immix Biopharma, Inc. profitable?
- Immix Biopharma, Inc. is not currently profitable: it reported a net loss of $34.9M over the trailing twelve months.
- What is Immix Biopharma, Inc.'s earnings per share?
- Immix Biopharma, Inc.'s diluted EPS over the trailing twelve months is $-0.92.
- Where does Immix Biopharma, Inc.'s income statement data come from?
- Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.